CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro

Folia Neuropathologica

Volumn 46, Issue 2, 2008, Pages 139-148

  Matyja, Ewa ^a   Taraszewska, Anna ^a   Nagańska, Ewa ^a   Grieb, Paweł ^a   Rafałowska, Janina ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

CDP choline; Excitotoxicity in vitro; Motor neuron degeneration; Neuroprotection

Indexed keywords

3 HYDROXYASPARTIC ACID; CITICOLINE; GLUTAMIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ORGANELLE; CONTROLLED STUDY; CYTOPLASM; DRUG EXPOSURE; ENDOPLASMIC RETICULUM; EXCITOTOXICITY; IN VITRO STUDY; LUMBAR SPINAL CORD; MOTONEURON; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; RAT; TISSUE CULTURE;

EID: 48049109616     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002; 15: 133-139.
2. Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem 2002; 80: 12-23.
3. Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res 2003; 73: 308-315.
4. Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol 1999; 21: 633-664.
5. Araque A, Sanzgiri RP, Parpura V, Haydon PG. Astrocyte-induced modulation of synaptic transmission. Can J Physiol Pharmacol 1999; 77: 699-706.
6. Barrachina M, Dominguez I, Ambrosio S, Secades J, Lozano R, Ferrer I. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. J Neurol Sci 2003; 15: 105-110.
7. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, Cleveland DW. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-338.
8. Cakir E, Usul H, Peksoylu B, Sayin OC, Alver A, Topbas M, Baykal S, Kuzeyli K. Effects of citicoline on experimental spinal cord injury. J Clin Neurosci 2005; 12: 923-926.
9. Choi DW, Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 623-634.
10. Clark W, Gunion-Rinker L, Lessov N, Hazel K. Citicoline treatment for experimental intracerebral hemorrhage in mice. Stroke 1998; 29: 2136-2140.
11. Conant R, Schauss AG, Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Altern Med Rev 2004; 9: 17-31.
12. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-695.
13. Danbolt NC, Chaudhry FA, Dehnes Y, Lehre KP, Levy LM, Ullensvang K, Storm-Mathisen J. Properties and localization of glutamate transporters. Prog Brain Res 1998; 116: 23-43.
14. Farooqui AA, Yang HC, Horrocks L. Involvement of phospholipase A2 in neurodegeneration. Neurochem Int 1997; 30: 517-522.
15. Ferri A, Nencini M, Casciati A, Cozzolino M, Angelini DF, Longone P, Spalloni A, Rotilio G, Carri MT. Cell death in amyotrophic lateral sclerosis: interplay between neuronal and glial cells. FASEB J Epub 2004; 18: 1261-1263.
16. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005; 18: CD000269.
17. Gadomski R, Chrapusta SJ, Wojda R, Grieb P. Morphological changes and selective loss of motoneurons in the lumbar part of the spinal cord in a rat model of familial amyotrophic lateral sclerosis (fALS). Folia Neuropathol 2006; 44: 154-161.
18. Grieb P, Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J Neurosci Res 2002; 15: 143-148.
19. Hansson E, Blomstrand F, Khatibi S, Olsson T, Rönnbäck L. Glutamate induced astroglial swelling - methods and mechanisms. Acta Neurochir Suppl 1997; 70: 148-151.
20. Herbik MA, Chrapusta SJ, Kowalczyk A, Grieb P. Maintenance of the rat transgenic model of familial amyotrophic lateral sclerosis expressing human SOD1G93A mutation. Folia Neuropathol 2006; 44: 149-153.
21. Hurtado O, Moro MA, Cardenas A, Sanchez V, Fernandez-Tome P, Leza JC, Lorenzo P, Secades JJ, Lozano R, Davalos A, Castillo J, Lizasoain I. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis 2005; 18: 336-345.
22. Krupinski J, Slevin M, Badimon L. Citicoline inhibits MAP kinase signalling pathways after focal cerebral ischaemia. Neurochem Res 2005; 30: 1067-1073.
23. Laming PR, Kimelberg H, Robinson S, Salm A, Hawrylak N, Müller C, Roots B, Ng K. Neuronal-glial interactions and behaviour. Neurosci Biobehav Rev 2000; 24: 295-340.
24. Lin CL, Tzingounis AV, Jin L, Furuta A, Kavanaugh MP, Rothstein JD. Molecular cloning and expression of the rat EAAT4 glutamate transporter subtype. Brain Res Mol Brain Res 1998; 63: 174-179.
25. Lockshin RA, Zakeri Z. Apoptosis, autophagy, and more. Int J Biochem Cell Biol 2004; 36: 2405-2419.
26. López G-Coviella I, Agut J, Ortiz JA, Wurtman RJ. Effects of orally administered cytidine 5′-diphosphate choline on brain phospholipid content. J Nutr Biochem 1992; 3: 313-315.
27. Matyja E, Nagańska E, Taraszewska A, Rafałowska J. The mode of spinal motor neurons degeneration in a model of slow glutamate excitotoxicity in vitro. Folia Neuropathol 2005; 43: 7-13.
28. Matyja E, Taraszewska A, Naganska E, Rafalowska J. Autophagic degeneration of motor neurons in a model of slow glutamate excitotoxicity in vitro. Ultrastruct Pathol 2005; 29: 331-339.
29. Matyja E, Taraszewska A, Nagańska E, Rafałowska J, Gebarowska J. Astroglial alterations in amyotrophic lateral sclerosis (ALS) model of slow glutamate excitotoxicity in vitro. Folia Neuropathol 2006; 44: 183-190
30. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379-387.
31. Mir C, Clotet J, Aledo R, Durany N, Argemi J, Lozano R, Cervos-Navarro J, Casals N. CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. J Mol Neurosci 2003; 20: 53-60.
32. Nedergaard M. Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. Science 1994; 263: 1768-1771.
33. Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG. Glutamate-mediated astrocyte-neuron signalling. Nature 1994; 369: 744-747.
34. Radad K, Gille G, Xiaojing J, Durany N, Rausch WD. CDP-choline reduces dopaminergic cell loss induced by MPP(+) and glutamate in primary mesencephalic cell culture. Int J Neurosci 2007; 117: 985-998.
35. Rafałowska J, Fidziańska A, Dziewulska D, Gadomski R, Ogonowska W, Grieb P. Progression of morphological changes within CNS in a transgenic rat model of familial amyotrophic lateral sclerosis. Folia Neuropathol 2006; 44: 162-174.
36. Rothstein JD, Martin LJ, Kuncl RW. Decreased gluta mate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326: 1464-1468.
37. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 1993; 90: 6591-6595.
38. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW. Localization of neuronal and glial glutamate transporters. Neuron 1994; 13: 713-725.
39. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73-84.
40. Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995; 68: 7-20.
41. Rothstein JD. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci 1995; 96: 348-359.
42. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006; 28 Suppl B: 1-56.
43. Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, Marouan A, Dib M, Meininger V. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002; 193: 73-78.
44. Svennerholm L, Gottfries CG. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 1994; 62: 1039-1047.
45. Trotti D, Rolfs A, Danbolt NC, Brown RH Jr, Hediger MA. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999; 2: 848.
46. Trovarelli G, de Medio GE, Dorman RV, Piccinin GL, Horrocks LA, Porcellati G. Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil. Neurochem Res 1981; 6: 821-833.
47. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995; 56: 637-660.
48. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
49. Yuan J, Lipinski M, Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron 2003; 40: 401-413.
50. Yucel N, Cayli SR, Ates O, Karadag N, Firat S, Turkoz Y. Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioral and neuroanatomical recovery. Neurochem Res Epub 2006; 31: 767-775.
51. Zweifler RM. Membrane stabilizer: citicoline. Curr Med Res Opin 2002; 18 Suppl 2: 14-17.